Keytruda Combination Gives Celyad’s Off-The-Shelf CAR-T A Shot In The Arm
Allogeneics Still Waiting For Breakthrough
Executive Summary
Celyad has been in the CAR-T field for many years, but hopes that a new focus on allogeneic platforms and new targets will put it ahead of competitors.
You may also be interested in...
KRAS Inhibitors Show Promise But Long Road Ahead, Say Experts
Harvard Medical School’s Dr. Bruce Chabner, Bayer Pharma’s global head of research and Roivant Sciences founder, among others, share their views on the challenges and path ahead for KRAS inhibitors and other oncology modalities including CAR-T therapy.
Speculation Grows On Potential Big Pharma Buyout Of Mirati
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.
Arvinas And Pfizer’s Protein Degrader Shows Mixed Results In Breast Cancer
The frontrunner in the new protein degrader class has shown lackluster Phase II results in breast cancer, but Arvinas hopes for success in less heavily pre-treated patients in Phase III.